

Innospec REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Strong contributions from all businesses with revenues up 12 percent and operating income up 16 percent
Continued strength in Fuel Specialties and further improvement in Performance Chemicals and Oilfield Services
Debt-free balance sheet with over $250 million in net cash; $6.4 million in share repurchases
GAAP EPS $1.25 and adjusted non-GAAP EPS $1.27
Englewood, CO – August 4, 2026 – Innospec Inc. (NASDAQ: IOSP) today announced its financial results for the second quarter ended June 30, 2026.
Total revenues for the second quarter were $491.4 million, an increase of 12 percent from $439.7 million in the corresponding period last year. Net income attributable to Innospec for the quarter was $30.8 million or $1.25 per diluted share compared to $23.5 million or 94 cents per diluted share recorded in the second quarter last year. Adjusted EBITDA for the quarter was $50.1 million compared to $49.1 million reported in the same period a year ago.
Results for this quarter include some special items, which are summarized in the table below. Excluding these items, adjusted non-GAAP EPS in the second quarter was $1.27 per diluted share, compared to $1.26 per diluted share a year ago.
Cash from operating activities was $7.2 million before capital expenditure of $16.5 million. The quarter closed with net cash of $250.2 million. In the second quarter, the Company paid its semi-annual dividend of 92 cents per common share and repurchased 87,089 of its common shares under the share repurchase program at a cost of $22.7 million and $6.4 million respectively.
Adjusted EBITDA and net income attributable to Innospec excluding special items and related per-share amounts together with net cash, are non-GAAP financial measures that are defined and reconciled with GAAP results herein and in the schedules below.
|
|
Quarter ended June 30, 2026 |
Quarter ended June 30, 2025 |
||||||
|
|
|
|
|
|
|
|
|
|
(in millions, except share and per share data) |
|
Net income attributable to Innospec |
|
Diluted EPS |
|
Net income attributable to Innospec |
|
Diluted EPS |
|
|
|
|
|
|
|
|
|
|
|
Reported GAAP amounts |
$ |
30.8 |
$ |
1.25 |
$ |
23.5 |
$ |
0.94 |
|
|
|
|
|
|
|
|
|
|
|
Foreign currency exchange (gains)/losses |
|
(0.9) |
|
(0.04) |
|
3.5 |
|
0.14 |
|
Amortization of acquired intangible assets |
|
0.8 |
|
0.03 |
|
1.6 |
|
0.06 |
|
Legacy costs of closed operations |
|
0.7 |
|
0.03 |
|
2.3 |
|
0.09 |
|
Adjustment to fair value of contingent consideration |
|
0.1 |
|
- |
|
0.8 |
|
0.03 |
|
|
|
0.7 |
|
0.02 |
|
8.2 |
|
0.32 |
|
|
|
|
|
|
|
|
|
|
|
Adjusted non-GAAP amounts |
$ |
31.5 |
$ |
1.27 |
$ |
31.7 |
$ |
1.26 |
|